Vol 18, No 3 (2019)
- Year: 2019
- Published: 13.09.2019
- Articles: 17
- URL: https://hemoncim.com/jour/issue/view/28
Full Issue
PROMISING STUDIES
Low-dose infusions of CD45RA depleted donor lymphocytes after TCRα/β-depleted transplantation in patients with non-malignant disorders
Abstract
Viral infections are frequent causes of failure among the recipients of the HSCT with graft TCRα/β and CD19depletion. Adoptive transfer of memory T-cells by CD45RA-depleted donor lymphocytes infusions (memory DLI) may be useful in control of viral infections. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The work reflects the retrospective data analysis of 51 patients with non-malignant disorders who had received low dose memory DLI after HSCT. Up to 3 doses of donor lymphocytes were administered. Median follow-up for alive patients was 30 (18–49) months. We did not observe any allergic reactions, septic complications after memory DLI. The cumulative incidence of a de novo acute GVHD after DLI was 10% (95% CI: 4–22). Among 41% patients (n = 21) was detected CMV in the blood. In 73% of them (n = 16) CMV was detected before first DLI. Among patients who received DLI, 53% (n = 27) had documented appearance of virus-specific lymphocytes in peripheral blood (ELISPOT assay).Thus, the infusion of memory T-cells at a dose of 25–100 αβ 103/kg body weight of the recipient for CD3+ in the case of HSCT from a haploidentical donor and 100–300 αβ 103/kg for an unrelated HSCT. Infusions of low dose memory T-lymphocytes after transplant engraftment are safe, potentially effective and constitute a simple measure to prevent infections in the setting of alpha/beta T-cell-depleted transplantation.



ORIGINAL ARTICLES
Epilemiological characteristics of Diamond–Blackfen anemia in pediatric population of the Russian Federation
Abstract
Diamond–Blackfen Anemia (DBA) is a rare, clinically and genetically heterogeneous disorder from the group of congenital syndromes of bone marrow failure. The purpose of this work is to identify the main medical-frequency characteristics of DBA (incidence, prevalence, mortality, cartographic analysis) in children in the Russian Federation during the observation period 2011–2016. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The Russian register of DBA patients, which had been developed and maintained since 2012 year by NMITS DGOI, was used to obtained epidemiological data and their analysis. At the end of 2018 year 141 patients from 137 families were included in the register. The average annual incidence rate of children with DBA for the Russian Federation was 0.63 ± 0.034, the average annual prevalence rate – 5.75 ± 0.87 per 100 thousand newborns born alive; mortality rate – 2.12%; the cartographic method of research showed that the largest number of patients was registered in the Central Federal District of the country, which is explained by the high population living in this district.



Peculiarities of hemostasis in infants with congenital heart diseases in the first 12 hours of their life
Abstract
The article is focused on the main parameters hemostasis and platelet count of newborns with congenital heart diseases who could require an early cardiac surgery during the first 12 hours of their life. Some known disorders of hemostasis in children with congenital heart diseases are described. A clinical case of the thrombotic complications in the child after cardiac surgery are presented, the tactic of drug therapy is described. The study was approved by the Independent Ethics Committee of the V.I. Kulakov Obstetrics, Gynecology and Perinatology Research Centre.



Immunophenotypic characterization of acute megakaryoblastic leukaemia in children
Abstract
Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia, in which the bone marrow produce increased numbers of immature abnormal megakaryoblasts. AMKL is rare both in children and adults, but is the most frequent subtype of acute myeloid leukemia (AML) in children with Down syndrome. Morphological diagnosis of this disease could be complicated, thus flow cytometry plays a crucial role in the diagnostics of AMKL. The aim of the present study was to investigate the immunophenotypic characteristics of AMKL in children. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The study group included 103 patients with AMKL. Antigen expression profile was assessed by multicolor flow cytometry. We identified three groups of patients according to different levels of CD45 expression, and in majority of patients (74%) high level of CD45 expression was detected. Significant immunophenotypic differences between these groups were found. In 56% of patients trisomy of 21 chromosome was detected. Among these patients, 86% belonged to group of high CD45 expression. Moreover, children with trisomy 21 represented the majority in the group with high level of CD45 expression (64%). Also, there were found several significant differences between patients with and without trisomy 21 within the group of high CD45 expression. This study demonstrated the wide immunophenotypic heterogeneity of AMKL. In general, the revealed diversity obviously reflects the biological heterogeneity of this AML subtype.



Fisher-Evans Syndrome in Children: an Analysis of Genetic Defects and Therapy Response
Abstract
The Fisher–Evans syndrome (FES), also known as Evans syndrome (ES) is an immune hemopathy characterized by bicytopenia or pancytopenia in the absence of other diseases. FES may be either primary/idiopathic, or secondary, occurring against the background of other diseases. In children, FES is frequently related to a primary immunodeficiency disorder (PID). This article presents a retrospective data analysis of a cohort of pediatric patients (n = 14) with FES, the aim of which is to demonstrate the necessity of conducting a molecular genetic investigation for PID diagnosis. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The patients from this cohort were presented at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology during the period 2012–2019. All of these patients underwent Next Generation Sequencing (NGS). The median age of disease onset was 5.5 years (from 5 months to 16 years). The male-to-female ratio was 1.8:1. Thanks to the results of the genetic investigation conducted on 14 patients with FES, it was possible to identify 10 children (71.4%) who had secondary FES. The median age of disease onset in patients with secondary FES was 4 years, the minimum age was 5 months, the maximum age was 12 years. The male-to-female ratio was 7:3. Most frequently, the disease onset was associated with ITP, immune thrombocytopenia (35.7% of patients) or simultaneously with ITP and AIHA, autoimmune hemolytic anemia (35.7% of patients); less frequently, the disease onset was associated with AIHA, with a subsequent occurrence of ITP (21.4% of patients). A pancytopenia was identified in 1 patient with FES associated with a PID. Among our patients with a disease onset associated with AIHA, there was not a single case with a PID. We noted an extremely low effectiveness of glucocorticoids and IVIgs for the treatment of FES: in practically 100% of cases, the patients in the analysed group required second and subsequent lines of therapy. Among other therapy types, effective for both primary and secondary FES, we should note rituximab (62% of patients stay in remission for up to 1 year) and MMF (80% of patients stay in remission for up to 1 year). On the basis of the conducted study we can conclude that male patients with FES under 18 years of age whose disease onset was associated with ITP need to be thoroughly tested for PID, including genetic testing, since patients in this group have the greatest PID incidence. Treating FES with glucocorticoids and IVIgs is nearly always not very effective and second and subsequent lines of therapy are required. The drugs of choice which are most effective for patients with FES are rituximab and MMF.



Combined treatment of diffuse sclerosing osteomyelitis of mandible in children
Abstract
Diffuse sclerosing osteomyelitis of the jaw (DSO) is a rare and poorly understood disease. Nowadays treatment protocols (steroid or painkillers, corticotomy) do not capable of to get good and stabile results or are associated with the development of potentially serious side effects. The treatment algorithm developed by us, including the course treatment with bisphosphonates, was well tolerated and capable of to get clinical and radiological remission in the case of previous decortication and antibacterial therapy was done. For these reasons, this treatment protocol is not without interest and need of further investigates. The study was approved by the Local Ethics Committee of Russian Children's Clinical Hospital.



CLINICAL OBSERVATIONS
ANKRD26-related thrombocytopenia: case report and literature review of inherited thrombocytopenias with predisposition to malignancies
Abstract
ANKRD26-related thrombocytopenia (previously known as thrombocytopenia-2) is a rare form of inherited platelet disorders. Patients with ANKRD26-related thrombocytopenia usually do not suffer from severe bleeding but have predisposition to acute myeloid leukemia and other malignancies. Patients with ANKRD26-related thrombocytopenia and their relatives need genetic consultation and long term follow-up in view of risk of malignant blood disorders. The clinical case of ANKRD26-related thrombocytopenia in two siblings is presented in this paper. Review of literary data on pathogenesis, treatment and follow-up of patients with ANKRD26-related thrombocytopenia is performed. Common questions of diagnosis and management in patients with congenital thrombocytopenias with predisposition to malignant blood disorders are also reviewed. Parents gave their permission for using personal data for clinical research and publications.



Family case hemolytic anemia due to abnormal unstable hemoglobin with low oxygen affinity (Hb Cheverly)
Abstract
Hereditary hemolytic anemia caused by unstable hemoglobin is a rare pathology, characterized by variability of clinical manifestations. This disease is characterized by the hemolytic crises, which are frequently associated with infections or taking drugs that cause hemolysis. Age of debut depends on which of the globin chains mutation occurs. Among these diseases, hemolytic anemia associated with the presence of a structurally abnormal unstable hemoglobin with low oxygen affinity in the erythrocytes is a special group. With this type of abnormal hemoglobin, pulse oximetry demonstrates falsely low oxygen saturation of the blood, with increased oxygen delivery to the tissues. It is important to identify unstable hemoglobin in order to avoid the misinterpretation of low oxygen saturation during the pulse oximetry in emergency cases, surgeries or intensive therapy. The article presents an analysis of the family with hereditary hemolytic anemia due to unstable hemoglobin Cheverly. The main clinical and diagnostic markers of the disease are described in detail. Parents gave their permission for using personal data for clinical research and publications.



Vitamin B12-deficiency anemia in infants: clinical presentation, current diagnostic and treatment
Abstract
Vitamin B12 (cobalamin) deficiency in infants exclusively breastfed is usually the result of its deficiency in the mothers (vegetarians or in the presence of unrecognized pernicious anemia or malabsorption syndrome). Cobalamin is crucial for the normal development of the nervous system, the production of erythrocytes and the synthesis of DNA. The classic manifestation of its deficiency is megaloblastic anemia and, in advanced cases, pancytopenia. However, infants often present neurological symptoms (fatigue, failure to thrive, regress of developmental skills, lethargy, motor disorders), as a consequence of inadequate myelination of the brain. Cobalamin treatment is effective in the most children, however, the neurological deficit varying degrees may persist. The long-term prognosis depends on overall duration of vitamin B12 deficiency and severity of symptoms. The article presents our own interesting clinical observations. Parents gave their permission for using personal data for clinical research and publications.



Syndromе associated with multiple venous malformations (Bean syndrome)
Abstract
Blue rubber bleb nevus syndrome (BRBNS) also called Bean's syndrome is a rare disorder characterized by mucocutaneous angiomatose multiple cutaneous venous malformations. Pathogenesis of the BRBNS is caused by the somatic mutations in angiopoietin receptor gene TEK. These mutations cause ligand-independent activation of the tyrosine kinase receptor and the PI3K / AKT pathway and involve the mTOR in the pathological process in a specific way. There are no universally effective methods for treating systemic forms of vascular malformations currently. However, recent numerous reports have shown the advantages of rapamycin, an mTOR inhibitor, as a well-tolerated and effective therapy in patients with vascular abnormalities, in particular with diffuse angiomatose. This article presents a clinical case of a 5-years old patient with a diagnosis of iron deficiency anemia, who has been treated for a long time and received iron supplements therapy without achieving any effect. The diagnosis of Bean's syndrome was established after 5 years from the first clinical manifestation and based on clinical, laboratory and instrumental methods. The cause of iron deficiency anemia was established. It was repeated chronic bleedings from multiple sites of the gastrointestinal mucosa vessels. Prescribed rapamycin therapy allowed to contain gastrointestinal bleeding, to reduce the size of vascular lesions and to prevent the formation of new ones. Parents gave their consent to use information about the child in the article.



Invasive aspergillosis in children in debut of acute myeloid leukemia
Abstract
Invasive aspergillosis (IA) is a life-threatening complication in pediatric patients with hematological malignancies. The highest incidence rates of IA were found in pediatric patients with acute myeloid leukemia (AML). We presented a case of successful treatment of IA in a patient with debut of AML with Down syndrome, analysis of IA cases in children with AML according data of the register and a literature review. 46 pediatric patients with IA were included, among them 16 (34.7%) with AML. In 3 (18.75%) pts AML was diagnosed in presentation of AML. Risk factors of IA were prolonged neutropenia (100%) and lymphocytopenia (81%). The most common clinical signs were: fever > 38.5 ºС (93.7%), cough (75%) and respiratory failure (43.7%). The lung involvement was diagnosed in 93.7% of pts, more than 2 sites of IA – in 12.5%, endophthalmitis – in 6.25%. Typical imaging finding was «halo sign» – 37.5%. According received results «probable IA» was diagnosed in 87.5% of pts and «proven» in 12.5%. Antifungal treatment received 100% of patients, with voriconazole only – 50%, combined antifungal therapy – 33.3%. Overall 12-week survival was 87.5%. Parents patients agreed to use personal data in research and publications.



Clericusio syndrome (poikiloderm with neutropenia)
Abstract
Clericusio syndrome is a rare genetic disease belonging to the group of congenital neutropenias, first described by S. Clericuzio et al. in 1991, in 14 patients from the Navajo tribe. It is characterized by poikiloderma and neutropenia, with recurrent infections and a high risk of developing myelodysplastic syndrome. Approaches to therapy are not optimized due to the rarity of this pathology. The article provides an overview of the data on the disease available to date, and discusses the case of Clericusio syndrome in a 5-year-old boy, from an early age observed in Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Parents gave their permission for using personal data for clinical research and publications.



SCHOOL OF IMMUNOLOGY – EXPERT OPINION
The phenomenon of reverse mutation in a patient with Wiskott–Aldrich syndrome
Abstract
Primary immunodeficiencies (PIDS) are genetically caused heterogeneous diseases of the immune system. One of the genetic phenomenon affecting the phenotypic diversity of PIDS is a reverse somatic mosaicism (RM) observed in different groups of PIDS. The majority of RM cases are described in patients with Wiskott–Aldrich syndrome (WAS). Despite the fact that PM does not always lead to a mild form of the disease, the presence of this phenomenon can cause the delay of diagnosis and start of the appropriate treatment. This article presents the case of a patient with Wiskott–Aldrich syndrome with a reverse mutation in the WAS gene. Parents gave their consent to use information about the child in the article.



LITERATURE REVIEW
Platelet functional activity: physiology and laboratory diagnostic methods
Abstract
Platelets perform numerous important functions not only in the process of normal functioning of hemostatic system, but also in other physiological processes, such as: vessel wall integrity regulation, wound healing, inflammatory response. Its malfunction can be found in various diseases and conditions (including oncohematological disorders, solid tumors, inflammatory diseases, sepsis, autoimmune disorders), is triggered by injury or medications and can lead to dangerous consequences, such as bleeding and thrombosis. However, platelets functional activity quantity assessment tools are extremely limited, the perception what platelet functional activity is about is also quite unclear. This review considers platelets function, its' abnormalities, possibilities for its' assessment by existing methods as well as promising directions for their development.



Reversible platelet aggregation in the presence of calcium ions: mechanisms and potential value
Abstract
Disorders in the functions of platelets – blood cells responsible for the blood clots formation and prevention – are observed as independent diseases, as a complication of cancer and hematological diseases or as a result of a therapy. Nowadays, a test of platelet aggregation by aggregometry is the only diagnostic method for assessing the platelets functions. There are several varieties of aggregometry, which differ both in the method of recording the formation of platelet aggregates and in the method of preparing platelets for the experiment. In most laboratories, it is customary to conduct aggregometry in platelet-rich plasma in the presence of citrate ions. In this case, the concentration of calcium ions in plasma decreases, it prevents the thrombin formation and the plasma coagulation. On the other hand, it has long been known that platelet aggregation in response to ADP in the presence of calcium ions (in blood plasma collected in heparin or hirudin tubes, also blocking plasma clotting) is reversible: after 1-5 minutes after the addition of the activator, the disaggregation begins until the light transmission of the solution (platelet concentration) returns to its original level. This phenomenon is called "reversible” platelet aggregation. Reversible aggregation (“disaggregation”) is sometimes observed in aggregometry of citrate plasma, especially in pediatric patients. However, it is usually not considered normal and is considered a sign of platelet dysfunction. This review considers the known mechanisms of disaggregation in the presence or absence of calcium ions in the medium. The role of secondary activation of platelets as a potential cause of irreversible aggregation is discussed, as well as possible versions for explaining the results of aggregometry, when reversible platelet aggregation is observed.



A modern view on the complement system
Abstract
Complement is a part of the immune system which provides host cells with protection against pathogen cells and particles. It is activated when a pathogen invasion is detected. The results of numerous investigations have led to growing realization of the important role of this system in maintaining normal organism homeostasis. This review summarizes a modern view on the complement system.



Relevance and management of secondary hypogammaglobulinema in clinical practice
Abstract
Advance protocols for the treatment most of oncology, hematology and some inherited disorders may lead to development severe secondary hypogammaglobulinaemia. Particularly, it is often caused by therapy with monoclonal antibodies binding B-cells (such as rituximab, belimumab, inotuzumab), therapy with inhibitors of tyrosine-kinase (imatinib, desatinib), as well as applying a variety of immunosuppressive and chemotherapy agents (steroids, azathioprine, cyclophosphamide etc.). It should be note, that chronic lymphoid leukemia and multiple myeloma could be complicated with hypogammaglobulinaemia, not only because of specific therapy, but also as features of the diseases. Hematopoietic stems cells transplantation can also lead to development severe and prolonged hypogammaglobulinaemia. This is associated with intensive immune/myeloablative therapy, as well as with immunologic reconstitution after transplantation. Modern intravenous immunoglobulins (IVIG) have a wide repertoire of pathogen-specific activity with high safety profile and constitute essential part of therapy patients with secondary hypogammaglobulinaemia. The paper presents literature review of IVIG usage in various clinical situations, as well as several clinical examples of personal experience.


